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ABSTRACT
We report a self-sufficient microfluidic paper-based lateral flow immunoassay device (μLFD) for highly sensitive detection of the thyroid-
stimulating hormone (TSH). Fabrication of the paper microchannels involves engraving the nitrocellulose membrane with a CO2 laser to
create narrow flow paths, which constrain the fluid flow over the test zone. The proposed microchannel modified devices were studied for
detection of the TSH using gold nanoparticles as labels. The effect of such microchannel modified LFDs has led to an improvement in
sensitivity by nine times and the limit of detection by 6.6 times due to the slow flow rate of the sample compared with the traditional LFD.
In addition, the binding of gold nanoparticles over the test line is more uniform in the case of the μLFD, thus minimizing leading-edge
effects, resulting in more accurate quantitative analysis. The proposed strategy offers great potential for multiplex detection of biomarkers
with increased sensitivity without introducing any hydrophobic materials to the LFD.
© 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/5.0026047
I. INTRODUCTION
Lateral flow immunoassay devices (LFDs) are suitable for rapid
detection of analytes from a finger prick blood sample in low
resource settings, are inexpensive and self-powered, and require a
small volume of the blood sample. The World Health Organization
(WHO) recognizes the importance of point of care (POC) devices
such as LFDs in diagnosing diseases and has established criteria for
evaluating such devices. Given the acronym “ASSURED,” the cri-
teria specify that devices should be “affordable, sensitive, specific,
user-friendly, rapid and robust, equipment-free, and deliverable to
end users.” Current LFDs are simple wicking-based devices, which
use gold nanoparticles (AuNPs) for detection of biomarkers. How-
ever, extensive use of LFDs is limited due to the lack of sensitivity
and reproducibility and due to quantitative analysis issues. One of
the main reasons for the lack of sensitivity is that the most commonly
observable labels such as AuNPs are not particularly sensitive. Labels
such as carbon nanomaterials,1–5 latex beads,1 fluorescent europium
nanoparticles,6 chemiluminescent labels,7 horseradish peroxidase-
conjugated AuNPs,8 graphene oxide coated with AuNPs,9 silver
nanoparticles,10 and platinum nanoparticles11–13 have all been used
to improve the performance of LFDs. There are several self-sufficient
paper-based devices that have been reported, which improve the per-
formance of the lateral flow assay in terms of reducing non-specific
binding, improving quality of test lines, and limit of detection.14–16
Zhang et al. have developed a self-contained microfluidic lateral flow
assay device, which enables delivery of the reagent and the sam-
ple through capillary action from two separate flow paths to reduce
non-specific binding of conjugate particles to the nitrocellulose (NC)
membrane. In addition, to avoid the uneven flow due to the 2D
microfluidic network, a liquid impermeable membrane was intro-
duced to mix the reagent and sample flows uniformly across the
test strip, which resulted in even test lines with good quantification
capability.17 Wang et al. have developed a self-powered microfluidic
device that incorporates filter paper for separation of plasma from
whole blood and an absorbent pad to induce capillary flow in the
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channels for rapid multiplexed detection of biomarkers from whole
blood.18
One of the critical factors that determine the performance of
the assay is the immunoreaction time between the antigen and the
capture antibody; thus, slower migration time of the sample over the
test line leads to increased sensitivity. Recent reports have shown
that decreasing the sample flow rate or stopping the flow temporar-
ily on the membrane by using novel techniques such as wax printing,
PDMS deposition, and use of tunable delay shunts on NC mem-
brane has led to improvement in LFD performance.19–24 Rivas et al.
have fabricated small diameter wax barriers at the starting of the NC
membrane to slow the sample flow, which resulted in improvement
in the limit of detection (LOD) by 2.6-fold when compared with
the unmodified NC membrane.19 Katis et al. constrained fluid flow
in a 1 mm wide channel and improved sensitivity by 62 times and
the LOD by 30 times when compared with an unmodified LFD.23
Simple modifications to the shapes of the NC membrane, conju-
gate pad, and sample pad have also shown improvement in LFD
performance.25 Zadehkafi et al. have shown that LFDs with a trape-
zoidal shaped NC membrane having a narrow width at the absorbent
pad and the position of the test line far from the conjugation pad
have shown improved performance by decreasing the LOD from
10 mIU/ml to 5 mIU/ml and increased test line intensities by
two times for the human chorionic gonadotropin biomarker when
compared with normal LFDs.26
In this study, a self-sufficient microfluidic paper-based lateral
flow immunoassay device (μLFD) was developed for sensitive detec-
tion of the thyroid-stimulating hormone (TSH). The fabricated nar-
row flow paths can constrain the same amount of fluid flow over the
smaller test zone, resulting in enhanced detection and removal of the
leading-edge binding effect. The narrow flow paths also act as self-
contained resistors, which decrease the fluid flow rate and increase
the immuno reaction time at the test line. Therefore, the narrow flow
paths act as a self-sufficient microfluidic system for enhanced detec-
tion of the TSH. The fabrication process involves engraving with a
CO2 laser to burn the NC membrane across its thickness, accord-
ing to the predesigned pattern.27–30 The process of forming narrow
flow paths is rapid: a typical NC membrane 2.5 cm wide and 35 cm
long can be engraved within 24 min to produce 55 devices. The pro-
cess does not require any additional hydrophobic materials, such
as wax or photo-polymers, which can result either in adsorption
of proteins or contamination of capture antibodies and decreases
LFD performance.27 The process of fabricating paper microchan-
nels is highly reproducible and suitable for the bulk manufacturing
process, enabling patterning techniques to be implemented in LFD
applications.
To show the advantages of such paper microchannels, we have
implemented the TSH as a model assay for a proof of principle study
to demonstrate the feasibility of the modified μLFDs. The TSH is
essential in maintaining the body’s metabolism and energetics. The
TSH plays a key role in developing physical and mental growth.31 It
is critical for the nervous, skeletal, and cardiovascular systems as well
as in regulating body temperature, heartbeat, and cholesterol.32–34
If a thyroid-related disease is untreated, several symptoms such as
excessive gain or loss of weight, cold intolerance, increased heart-
beat, infertility, and developing low bone density and a range of
autoimmune diseases can be observed.35,36 TSH levels are normally
measured either with finger prick blood samples or blood obtained
from the vein. The normal TSH concentration for healthy individ-
uals is in the range of 0.5 μIU/ml–5 μIU/ml.36,37 In the case of sub-
clinical hypothyroidism, TSH levels are in the range of 5 μIU/ml–
10 μIU/ml,38 and TSH levels above 10 μIU/ml are considered thyroid
failure.39 Here, we demonstrate the potential applicability of μLFDs
for the detection of TSH levels with nine times increased sensitivity
and 6.6 times improved LOD when compared with traditional LFDs.
The LOD by using μLFDs is 7.5 μIU/ml, making the new devices
useful for detection of the TSH in the clinical range. In addition, the
μLFD demonstrates potential feasibility for multiplex detection of
various biomarkers.40,41
II. MATERIALS AND METHODS
A. Reagents and materials
The monoclonal mouse anti-TSH antibody (10-2428, Fitzger-
ald) and monoclonal mouse anti-TSH antibody (10-2426, Fitzger-
ald) were used as capture and detection anti-bodies, respectively.
The TSH antigen derived from the human pituitary gland was
obtained from the NIBSC. TSH calibrators in serum were obtained
from Randox Laboratories. The nitrocellulose membrane (CN95,
UniSart) was obtained from Sartorius. The absorbent pad (Ahlstrom
Munksjö, A238, A222) was purchased from Kenosha Tapes. The
backing card (width 80 mm and thickness 0.015 in.) was pur-
chased from DCN. Carboxyl gold nanoparticles (40 nm, 40 OD)
were obtained from Expedeon. N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), phosphate buffered saline
(PBS), 2-(N-morpholino) ethanesulfonic acid (MES), Tris-buffered
saline (TBS), sodium phosphate monobasic monohydrate, sodium
phosphate dibasic monohydrate, and sucrose were all purchased
from Sigma-Aldrich.
B. Modification of gold nanoparticles (AuNPs)
with antibodies
The TSH detection antibody was purified using an Amicon
filter unit to remove any amine terminated molecules, which can
interfere in the conjugation process, and the purified antibodies were
resuspended in 10 mM potassium phosphate buffer of 7.4 pH. A
AuNP-TSH antibody conjugate was prepared by following the rec-
ommended protocol from Expedeon.42 In brief, AuNPs function-
alized with the carboxyl group were used to covalently bind TSH
antibodies by using water-soluble EDC.43 To 50 μl of AuNP sus-
pension (40 OD), 20 μl of 100 μg/ml TSH detection antibodies was
mixed followed by addition of 20 μl of 1 mM EDC. The resul-
tant solution was incubated for 30 min at room temperature. Then,
1 ml of TBS (containing 0.05% Tween) was added to the mixture and
centrifuged at 6200 rpm at 10 ○C for 10 min. The supernatant was
carefully removed, and the pellet of the AuNP-antibody was resus-
pended in 90 μl of 1XTBS, 0.5% BSA, and 0.05% Tween to obtain 20
OD of the conjugate.
C. Fabrication of LFDs and μLFDs
LFDs were prepared in three different configurations—(1)
traditional LFDs of 5 mm width, (2) single-channel μLFDs, and
(3) multi-channel μLFDs consisting of three parallel channels—as
shown in Fig. 1(b). Fabrication of μLFDs consists of two impor-
tant steps, as shown in Fig. 1(a): (1) dispensing capture antibodies
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FIG. 1. (a) Fabrication process of μLFDs and (b) three different formats of LFDs: traditional LFDs of 5 mm width, multi-channel μLFDs consisting of three parallel channels,
and single channel μLFDs.
on the NC membrane and (2) laser irradiation on the NC mem-
brane. In step 1, the capture antibodies were diluted in 10 mM phos-
phate buffer containing 1% of sucrose to obtain a concentration of
1 mg/ml. The anti-TSH antibody (10-2428) was dispensed onto the
NC membrane using a BioDot (ZX1010) dispensing platform at a
flow rate of 1 μl/cm to obtain a test line width of 1 mm. Then, the
NC membrane was dried in an oven at 37 ○C for 30 min. Step 2 was
performed by a Universal Laser Systems VLS2.30 equipped with a
10.6 μm wavelength pulsed CO2 laser system (25 W). A laser duty
cycle of 7.5%, scan rate of 20 cm/s, and image density of 1000 ppi
were used to fabricate paper microfluidic channels. After the fab-
rication process, the NC membrane was laminated onto a plastic
backing card followed by the absorbent pad with 3 mm overlap on
the NC membrane. We simplified the design of the LFD by elim-
inating the sample pad and the conjugate pad. Finally, strips were
cut 5 mm wide and stored in aluminum foil bags with a desiccant to
absorb moisture.
D. The lateral flow assay procedure
TSH antigen solutions of different concentrations ranging from
1000 μIU/ml to 5 μIU/ml were prepared in 10 mM PBS, a pH 8.0
buffer. To prepare the reaction solution, 5 μl of the Au conjugate
(5 OD) was mixed with 45 μl of the reaction buffer (10 mM PBS, 1%
BSA, and 0.05% Tween) and 10 μl of TSH antigen solution. Next,
60 μl of the reaction solution is added to each well of a 96-well plate.
The LFD was immersed into the sample well and allowed to react
until all the solution in the well diffused to the absorbent pad. After
the formation of the test line, the LFDs were dried and scanned using
an HP8600 scanner with 1200 dpi resolution, and the intensity of
the test lines was deduced using ImageJ software. LOD is defined
as the minimum concentration that is required to obtain a mean
intensity three times higher than the standard deviation of the blank,
without the antigen, when compared with the mean intensity of the
blank.44,45 Each set of experiments was repeated three times in order
to check the reproducibility of results.
III. RESULTS AND DISCUSSION
A number of antibodies for the TSH were sourced from dif-
ferent suppliers for suitability in LFDs. Different configurations
(n = 19) with regard to the capture and detection antibodies were
evaluated during the initial antibody screening and characterization
process. Initial experiments focused on spotting antibodies on the
NC membrane and assessing for sensitivity and non-specific bind-
ing. From this initial evaluation, it can be concluded that antibodies
obtained from Fitzgerald looked the most promising and were used
for the remainder of the study.
To evaluate the stability of the AuNP- TSH conjugate, UV-VIS
spectra were collected before and after the conjugation process to
measure the optical density (OD) of the conjugate. Figure 2 shows
a successful conjugation on gold nanoparticles where the resonance
peak is shifted to the right by about 4 nm (red shifted) due to the
effect of conjugated protein on the plasmon resonance peak of the
gold nanoparticle. In addition, the FWHM and OD of the conjugate
are the same as those of the gold nanoparticles, indicating that the
conjugate consists of monodispersed gold nanoparticles attached to
the detector antibody.
To enhance the analytical sensitivity of LFDs for TSH detec-
tion, a new μLFD was developed to decrease the fluid flow rate
without adding any additional components and maintaining the
traditional format. Fabrication of paper microchannels using CO2
was performed on the capture antibody deposited NC membrane,
as shown in Fig. 1(a), to obtain uniform width of the test line. It
was observed that dispensing antibodies using the BioDot on a pat-
terned NC membrane resulted in an uneven test line shape due to
the presence of the narrow flowpaths; therefore, antibodies were dis-
pensed first. Due to the small spot size (70 μm) and the pulsed mode
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FIG. 2. Shows the UV-VIS spectra of 40 nm gold nanoparticles before and after
conjugation (the inset shows the TEM image of the 40 nm gold nanoparticles).
operation of the CO2 laser, antibodies did not burn during the
engraving process of the NC membrane. By following this proce-
dure, paper microchannels of 0.5 mm width were fabricated without
damaging the antibodies. To fabricate the paper microchannels, the
NC membrane next to the channels was completely etched to make
the fluid flow constrained to the designed pathways, as shown in
Fig. 1(b).
LFDs were prepared in three different configurations: (1) tradi-
tional LFDs of 5 mm width, (2) single-channel μLFDs, and (3) multi-
channel μLFDs consisting of three parallel channels, as shown in
Fig. 1(b). Single-channel and multi-channel devices were fabricated
with channel widths of 0.5 mm and 1 mm, respectively. The TSH
assay was evaluated on all the strips with varying concentrations,
as shown in Fig. 3, and the intensities of the test line were evalu-
ated using ImageJ. The color test lines were selected, and the average
intensity values were measured. These values were subtracted from
the background noise, which was measured by taking the average of
the intensity values before and after the test lines for each individual
strip.
First, the performance of the LFDs consisting of absorbent pads
A222 and A238 was studied for the TSH assay. Absorbent pads A222
and A238 have wicking rates of 20 s/4 cm and 150 s/4 cm, respec-
tively. The LFD laminated with A222 is referred to as the traditional
LFD. The LFD laminated with A222 showed an LOD of 50 μIU/ml,
while using an LFD laminated with A238, an LOD of 20 μIU/ml was
obtained. This shows that using a lower wicking rate absorbent pad
results in a 2.5-fold improvement in the LOD and an increase in test
line intensities. In addition, leading-edge binding is observed more
prominently on the LFD laminated with the A222 absorbent pad due
to the high wicking rate.
To further improve the performance of the LFD, the NC mem-
brane was patterned in the form of microchannels. For μLFDs,
the absorbent pad A238 was used. For an analyte concentration of
1000 μIU/ml, the test line intensity increased 3.5 times on 0.5 mm
width constriction when compared with traditional LFDs. It was
observed that for lower concentrations, from 250 μIU/ml to 50
μIU/ml, the test line intensities were nine times higher on the 0.5
mm channel constriction when compared with traditional LFDs.
For this device, the LOD was found to be 7.5 μIU/ml, a 6.6-fold
enhancement when compared with the traditional LFD.
In the case of multiplex μLFDs of 0.5 mm channel width, the
test line intensities are three times higher than those of traditional
LFDs at an antigen concentration of 1000 μIU/ml. For analyte con-
centrations from 250 μIU/ml to 50 μIU/ml, the test line intensities
were six times higher when compared with traditional LFDs. Multi-
plex μLFDs with 0.5 mm channel width exhibited 7.5 μIU/ml as the
LOD, which indicates a 6.6-fold increase in the LOD when compared
FIG. 3. Scanned images of LFDs and μLFDs after the TSH assay performed at various concentrations ranging from 1000 μIU/ml to 5 μIU/ml: (a) the LFD of 5 mm width
attached to the A222 absorbent pad (considered as the traditional LFD), (b) the LFD of 5 mm width attached to the absorbent A238, (c) and (d) multiplex channel μLFDs of
1 mm and 0.5 mm channel widths, and (e) and (f) single channel μLFDs of 1 mm and 0.5 mm channel widths. The asterisks (∗) indicate the LOD.
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FIG. 4. (a) Average test line intensities at various concentrations of the TSH on all LFDs and (b) test line intensity profiles on all devices at 1000 μIU/ml concentration of the
TSH.
with traditional LFDs. The multiplex format of the μLFD is more
suitable for detection of multiple biomarkers on one single strip
with increased sensitivity when compared with traditional LFDs. A
detailed comparison of the test line intensities on various formats of
LFDs is shown in Fig. 4(a).
In the case of traditional LFDs, the test line intensities were
not uniformly distributed, i.e., higher intensities were present at the
beginning of the test line, and weaker intensities were present at the
end of the test line, while uniform binding of AuNPs over the test
line was formed for μLFDs due to the narrow flow paths, as shown
in Fig. 4(b). It can be observed that binding of the AuNPs is more
uniform in the case of 0.5 mm μLFDs. Thus, leading edge binding
is minimized in the case of μLFDs, which can result in an accu-
rate quantitative analysis of biomarkers by using lateral flow assay
readers.
In the case of multiplex μLFDs, absorbent pads (A222 and
A238) have not shown any difference on the brightness of the test
line, as shown in Fig. 5(a). In addition, for multiplex μLFDs, the
brightness of the test lines was the same when measured in serum
samples, as shown in Fig. S1. This indicates that in the case of μLFDs,
only patterning significantly lowers the flow rate so that the effect of
the absorbent pad or viscosity of the samples is nullified. To investi-
gate the effect of constriction width on the multiplex devices, μLFDs
were fabricated with four channels where the width of alternating
channels is 1 mm and 0.5 mm, as shown in Fig. S2. It has been
observed that the brightness of the test line is the same on both
1 mm and 0.5 mm channels, as shown Fig. S3. In addition, the
brightness of the test line is the same as in the case of the device
consisting of three channels of 1 mm width. This indicates that the
brightness of the test line depends on the total width of the channels
but not on the width of the single channel in the device.
For all the formats of LFDs, the wicking time for 60 μl of
the sample solution is shown in Fig. 5(b). It can be observed from
Fig. 5(b) that the 0.5 mm channel provides a slow flow rate and the
LFD consisting of the absorbent pad A222 provides a faster flow rate.
Accordingly, a decrease in the LOD, an increase in sensitivity, and
uniform binding of AuNPs were observed on the LFD providing a
slower fluid flow rate and consisting of a smaller test zone.
FIG. 5. (a) Shows the brightness of the test line on 1 mm multiplex devices attached to A222 and A238 absorbent pads and (b) the assay time or wicking time for 60 μl of the
sample on various formats of LFDs.
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IV. CONCLUSIONS
We have presented a novel strategy for improving sensitiv-
ity and LOD by patterning the NC membrane with a CO2 laser
to constrain fluid flow. These paper microchannels decrease the
test area zone and fluid flow rate, thereby increasing reaction time
between the antigen and the capture antibody, leading to the effec-
tive formation of the immunocomplex over the test region. Different
designs were studied, and paper microchannels of 0.5 mm width
exhibited improvement in sensitivity by nine times and LOD by
6.6 times when compared with the traditional LFD. The enhance-
ment in width LOD up to 7.5 μIU/ml can make μLFDs suitable for
detection of TSH levels in the clinical domain. This approach of cre-
ating narrow constrictions is simpler, is less time consuming, does
not require any additional materials to create hydrophobic barriers,
and does not need any alterations to the configuration of the LFD
when compared with wax printed devices. The proposed method
can extend the scope of the LFD with patterned techniques to enable
its use in a broad range of applications. This study has shown some
very promising data and considerations that are worthy of further
research to determine its suitability for a commercial diagnostic test.
Further research will be carried out toward multiplex detection of
biomarkers including control lines by using serum samples with a
complete device geometry.
SUPPLEMENTARY MATERIAL
See the supplementary material for experimental data related to
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